Henk M. Lokhorst
About
Henk M. Lokhorst is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Henk M. Lokhorst has authored 170 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Hematology, 81 papers in Oncology and 73 papers in Molecular Biology. Recurrent topics in Henk M. Lokhorst's work include Multiple Myeloma Research and Treatments (119 papers), Protein Degradation and Inhibitors (35 papers) and Peptidase Inhibition and Analysis (29 papers). Henk M. Lokhorst is often cited by papers focused on Multiple Myeloma Research and Treatments (119 papers), Protein Degradation and Inhibitors (35 papers) and Peptidase Inhibition and Analysis (29 papers). Henk M. Lokhorst collaborates with scholars based in Netherlands, United States and Denmark. Henk M. Lokhorst's co-authors include Niels W.C.J. van de Donk, Tuna Mutis, Pieter Sonneveld, Sonja Zweegman, A. Kate Sasser, Andries C. Bloem, Torben Plesner, Tahamtan Ahmadi, Inger S. Nijhof and Paul W.H.I. Parren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Experimental Medicine.
In The Last Decade
Henk M. Lokhorst
162 papers receiving 8.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Henk M. Lokhorst Netherlands | 47 | 5.3k | 3.8k | 3.8k | 1.7k | 1.3k | 170 | 8.1k | ||
| Niels W.C.J. van de Donk Netherlands | 50 | 5.3k 1.0× | 5.1k 1.3× | 3.7k 1.0× | 2.2k 1.3× | 1.0k 0.8× | 267 | 8.9k | ||
| Jonathan L. Kaufman United States | 45 | 5.2k 1.0× | 3.6k 0.9× | 5.0k 1.3× | 944 0.5× | 964 0.8× | 323 | 7.9k | ||
| Suzanne Lentzsch United States | 41 | 4.9k 0.9× | 3.4k 0.9× | 4.5k 1.2× | 830 0.5× | 920 0.7× | 227 | 7.2k | ||
| Bruno Paiva Spain | 36 | 3.4k 0.6× | 1.9k 0.5× | 2.6k 0.7× | 804 0.5× | 829 0.6× | 157 | 4.7k | ||
| Peter M. Voorhees United States | 33 | 2.9k 0.5× | 2.7k 0.7× | 3.3k 0.9× | 600 0.3× | 474 0.4× | 172 | 5.3k | ||
| Aldo M. Roccaro United States | 50 | 2.9k 0.5× | 2.0k 0.5× | 4.5k 1.2× | 1.3k 0.8× | 1.6k 1.2× | 203 | 7.6k | ||
| Marta Chesi United States | 40 | 4.0k 0.8× | 2.2k 0.6× | 5.2k 1.4× | 943 0.5× | 817 0.6× | 119 | 7.2k | ||
| Alexander M. Lesokhin United States | 36 | 1.7k 0.3× | 5.3k 1.4× | 1.8k 0.5× | 3.3k 1.9× | 653 0.5× | 195 | 7.5k | ||
| Javier Pinilla‐Ibarz United States | 41 | 2.6k 0.5× | 1.8k 0.5× | 1.9k 0.5× | 1.4k 0.8× | 2.3k 1.8× | 236 | 5.8k | ||
| R. Eric Davis United States | 46 | 1.3k 0.2× | 2.6k 0.7× | 3.8k 1.0× | 2.7k 1.6× | 1.9k 1.5× | 161 | 8.4k |
Countries citing papers authored by Henk M. Lokhorst
Since
Specialization
Citations
This map shows the geographic impact of Henk M. Lokhorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henk M. Lokhorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henk M. Lokhorst more than expected).
Fields of papers citing papers by Henk M. Lokhorst
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Henk M. Lokhorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henk M. Lokhorst. The network helps show where Henk M. Lokhorst may publish in the future.
Co-authorship network of co-authors of Henk M. Lokhorst
This figure shows the co-authorship network connecting the top 25 collaborators of Henk M. Lokhorst. A scholar is included among the top collaborators of Henk M. Lokhorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henk M. Lokhorst. Henk M. Lokhorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Belch, Andrew, Torben Plesner, Paul G. Richardson, et al.. (2024). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Carolina Digital Repository (University of North Carolina at Chapel Hill).
2.
Wester, Ruth, Bronno van der Holt, Sonja Zweegman, et al.. (2019). Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica. 104(11). 2265–2273.
3.
Drent, Esther, Renée Poels, Ruud Ruiter, et al.. (2019). Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells. Clinical Cancer Research. 25(13). 4014–4025.
4.
Pont, Margot J., Rimke Oostvogels, Cornelis A.M. van Bergen, et al.. (2019). T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells. Cancer Immunology Research. 7(5). 797–804.
5.
Krejcik, Jakub, Inger S. Nijhof, Berris van Kessel, et al.. (2017). Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research. 23(24). 7498–7511.
6.
Usmani, Saad Z., Hareth Nahi, Brendan M. Weiss, et al.. (2017). Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius. Blood. 130. 3107–3107.
7.
Horst, Hilma J. van der, Marije B. Overdijk, Esther C.W. Breij, et al.. (2017). Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding. Blood. 130. 1835–1835.
8.
Nijhof, Inger S., Tineke Casneuf, Berris van Kessel, et al.. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 128(7). 959–970.
9.
Clemens, Pamela L., Xiaoyu Yan, Henk M. Lokhorst, et al.. (2016). Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. Clinical Pharmacokinetics. 56(8). 915–924.
10.
Kuiper, Rowan, Mark van Duin, Martin H. van Vliet, et al.. (2015). Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 126(17). 1996–2004.
11.
Sonneveld, Pieter, Hartmut Goldschmidt, Laura Rosiñol, et al.. (2013). Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology. 31(26). 3279–3287.
12.
Guichelaar, Teun, Maarten E. Emmelot, Henk Rozemuller, et al.. (2013). Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells. Clinical Cancer Research. 19(6). 1467–1475.
13.
Donk, Niels W.C.J. van de, Monique C. Minnema, Julie H. Huang, et al.. (2013). Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. Clinical Cancer Research. 19(20). 5591–5601.
14.
Nijhof, Inger S., Sonja Zweegman, Mark‐David Levin, et al.. (2013). Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study). Blood. 122(21). 287–287.
15.
Holt, Bronno van der, Marie José Kersten, Sonja Zweegman, et al.. (2011). Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 118(9). 2413–2419.
16.
Lokhorst, Henk M., Corien Eeltink, Gerwin Huls, et al.. (2010). Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. Clinical Lymphoma Myeloma & Leukemia. 10(2). 138–143.
17.
Groen, Richard W.J., Frans M.A. Hofhuis, Berris van Kessel, et al.. (2010). In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma. Blood. 116(21). 3058–3058.
18.
Minnema, Monique C., Bronno van der Holt, Marie José Kersten, et al.. (2009). First Interim Analysis of HOVON 76: Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood. 114(22). 2285–2285.
19.
Corthals, Sophie L., Mojca Jongen‐Lavrencic, Yvonne de Knegt, et al.. (2009). Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leukemia Research. 34(5). 677–681.
20.
Beum, Paul V., Margaret A. Lindorfer, Frank J. Beurskens, et al.. (2008). Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis. The Journal of Immunology. 181(1). 822–832.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Niels W.C.J. van de Donk Breakdown of academic impact, for papers by Jonathan L. Kaufman Breakdown of academic impact, for papers by Suzanne Lentzsch Breakdown of academic impact, for papers by Bruno Paiva Breakdown of academic impact, for papers by Peter M. Voorhees Breakdown of academic impact, for papers by Aldo M. Roccaro Breakdown of academic impact, for papers by Marta Chesi Breakdown of academic impact, for papers by Alexander M. Lesokhin Breakdown of academic impact, for papers by Javier Pinilla‐Ibarz Breakdown of academic impact, for papers by R. Eric Davis